The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2020Evaluating the Role of Natural Killer Cells in Parkinson's Pathology
Promising Outcomes of Original Grant:
Our original study investigated whether immune cells called human natural killer (NK) cells play a protective role on the nervous system in Parkinson’s disease... -
Therapeutic Pipeline Program, 2020Therapeutic Swallow Sensor
Study Rationale:
Trouble swallowing is a common problem for people with Parkinson’s disease, occurring in up to 80 percent of cases. Swallowing problems can lead to drooling, increased risk of... -
Therapeutic Pipeline Program, 2020Dual-task Augmented Reality Treatment (DART) Protocol for Parkinson’s Disease
Study Rationale:
Approximately 80 percent of people with Parkinson’s disease fall due to problems with posture, walking and balance, known as postural and gait dysfunction (PIGD) one or more times a... -
Access to Data and Biospecimens, 2020Association of Repetitive DNA Elements in Parkinson’s Disease Risk and Progression
Study Rationale:
Repetitive DNA elements such as “jumping genes” were previously considered ‘junk DNA’. However, it is now known that these elements are involved in the development of several diseases... -
Research Grant, 2019Long-acting GM-CSF Fusion Protein (PDM608) for the Treatment of Parkinson’s Disease
Study Rationale:
Emerging evidence suggests that the modulating the peripheral immune system can be a powerful disease-modifying approach for the treatment of Parkinson's disease (PD). We have... -
Therapeutic Pipeline Program, 2019Oligomeric Alpha-synuclein-specific Antibody-based Gene Therapy
Study Rationale:
Alpha-synuclein is the primary component of Lewy bodies, the hallmark of Parkinson’s disease (PD). In particular, soluble aggregates of alpha-synuclein, also referred to as oligomers...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.